{"title":"赛克斯家庭把赛克斯家具和乔凡妮联系在一起","authors":"Almut Meyer-Bahlburg","doi":"10.1055/a-2176-1488","DOIUrl":null,"url":null,"abstract":"Brunner HI, Foeldvari I, Alexeeva E et al; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis 2023; 82(1): 154–160. doi: 10.1136/ard-2022-222849. Epub 2022 Aug 12. PMID: 35961761","PeriodicalId":478354,"journal":{"name":"Kinder- und Jugendmedizin","volume":"162 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Zulassung von Secukinumab für Kinder und Jugendliche mit juveniler Psoriasisarthritis und Enthesitis-assoziierter JIA\",\"authors\":\"Almut Meyer-Bahlburg\",\"doi\":\"10.1055/a-2176-1488\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Brunner HI, Foeldvari I, Alexeeva E et al; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis 2023; 82(1): 154–160. doi: 10.1136/ard-2022-222849. Epub 2022 Aug 12. PMID: 35961761\",\"PeriodicalId\":478354,\"journal\":{\"name\":\"Kinder- und Jugendmedizin\",\"volume\":\"162 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kinder- und Jugendmedizin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2176-1488\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kinder- und Jugendmedizin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2176-1488","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Zulassung von Secukinumab für Kinder und Jugendliche mit juveniler Psoriasisarthritis und Enthesitis-assoziierter JIA
Brunner HI, Foeldvari I, Alexeeva E et al; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis 2023; 82(1): 154–160. doi: 10.1136/ard-2022-222849. Epub 2022 Aug 12. PMID: 35961761
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
